Meeting
2023 ASCO Annual Meeting
Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.
Authors
Lauren Diaz Boyle
The University of Texas Health Science Center-San Antonio, San Antonio, TX
Lauren Diaz Boyle , Munaf Alkadimi , Maria Elena Fierro , Kana Lucero , Kathleen Franklin , Michael Mader , Zohra Nooruddin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4109)
DOI
10.1200/JCO.2023.41.16_suppl.4109
Abstract #
4109
Poster Bd #
430
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
First Author: Leijuan Gan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
First Author: Timothy J Brown
Poster
2022 ASCO Annual Meeting
High atezolizumab antidrug antibody levels are associated with unfavorable clinical outcomes and diminished T cell responses following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
First Author: Hong Jae Chon